Ridlor

Ridlor Warnings

clopidogrel

Manufacturer:

Mega Lifesciences

Distributor:

Maxxcare
Full Prescribing Info
Warnings
Reduced effectiveness due to impaired CYP2C19 function.
The inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19. This metabolism can be impaired by genetic variations in CYP2C19 and by concomitant medications that interfere with CYP2C19. Avoid use of Ridlor in patients with impaired CYP2C19 function due to known genetic variation or due to drugs that inhibit CYP2C19 activity.
Genetic Variations: Patients with genetically reduced CYP2C19 function have diminished antiplatelet responses and generally exhibit higher cardiovascular event rates following myocardial infarction than do patients with normal CYP2C19 function.
Thrombotic Thrombocytopenic Purpura (TTP): TTP has been reported rarely following use of clopidogrel, sometimes after a short exposure (<2 weeks). TTP is a serious condition that can be fatal and requires urgent treatment including plasmapheresis (plasma exchange). It is characterized by thrombocytopenia, microangiopathic hemolytic anemia [schistocytes (fragmented RBCs) seen on peripheral smear], neurological findings, renal dysfunction and fever.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in